GeneDx Holdings Corp. (NASDAQ: WGS) reported a targeted insider transaction this month when Chief Financial Officer Kevin Feeley disposed of 6,187 shares of Class A common stock on March 4, 2026, according to a Securities and Exchange Commission Form 4 filing. The shares were sold at prices between $77.6261 and $79.2492, producing proceeds of $486,370.
The filing states the sale was carried out to cover tax withholding obligations tied to the vesting and settlement of a performance-based restricted stock unit (RSU) award. The transaction is narrowly procedural in nature per the disclosure: it was not described as a discretionary sale but rather a mechanism to meet the tax liabilities created by an equity award vesting.
One day earlier, on March 3, the filing shows that Feeley received equity awards tied to the company’s compensation program. The record shows an issuance of 15,262 shares of Class A common stock with a reported value of $0, and an award of 10,865 restricted stock units. The Form 4 does not assign a monetary value to the 15,262 shares in that line, consistent with common reporting where shares issued in settlement may be recorded separately from any cash consideration.
On the market, GeneDx shares were trading at $82 at the time of reporting, down 37% year-to-date. Analyst coverage remains divergent: price targets among brokers referenced in company reporting and filings range from $130 to $177. An InvestingPro analysis noted in the filing commentary described the stock as appearing slightly overvalued at current market levels.
The filing and market commentary also highlighted recent price volatility. Over the trailing 12-month period, shares have traded as low as $55.17 and as high as $170.87, a span highlighted in the InvestingPro tip included with the regulatory disclosure.
These insider developments coincided with GeneDx’s fourth-quarter financial disclosure, which produced mixed signals about near-term performance and growth. The company reported quarterly revenue of $121.0 million, a 27% increase year-over-year and a modest beat versus the consensus estimate of $120.4 million. Revenue from Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) totaled $104.0 million, up 32% from the prior year and in line with expectations.
Despite the top-line strength, GeneDx missed earnings expectations for the quarter. In response, BTIG trimmed its price target from $200 to $170 while retaining a Buy rating. Canaccord Genuity maintained its Buy rating with a $170 target, and TD Cowen kept a Buy stance with a $165 target, noting the company’s focus on revenue growth drivers for fiscal 2026.
Management continues to guide growth from the core business, anticipating 25% to 27% expansion from its base operations, with additional upside expected from new market entries. These projections were reiterated in analyst commentary accompanying post-quarter revisions.
Collectively, the regulatory filing and the quarterly report offer investors a concise view of insider activity, near-term financial performance, analyst positioning, and the company’s stated growth assumptions. The sale by Feeley, framed as a tax-withholding action, sits alongside fresh equity awards and a backdrop of mixed financial data that has prompted both targeted price cuts and sustained Buy ratings from multiple firms.